Article Text

Download PDFPDF

TERT gene: its function and dysregulation in cancer
  1. Andrew J Colebatch1,
  2. Alexander Dobrovic2,3,4,5,
  3. Wendy A Cooper1,6,7
  1. 1 Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia
  2. 2 Translational Genomics and Epigenomics Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
  3. 3 School of Cancer Medicine and Molecular Cancer Prevention Program, La Trobe University, Melbourne, Victoria, Australia
  4. 4 Department of Clinical Pathology, The University of Melbourne, Parkville, Victoria, Australia
  5. 5 Department of Surgery, The University of Melbourne, Heidelberg, Victoria, Australia
  6. 6 Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia
  7. 7 School of Medicine, Western Sydney University, Sydney, New South Wales, Australia
  1. Correspondence to Dr Andrew J Colebatch, Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia; andrew.colebatch{at}


In this review, we summarise the function and structure of telomerase reverse transcriptase (TERT) in humans, including its regulation. The dysregulation of telomerase through TERT promoter mutations across a range of cancers is discussed. The molecular mechanism activated by TERT promoter mutations is outlined. Finally, the timing of TERT promoter mutations during carcinogenesis is reviewed in the context of their potential utility as clinical biomarkers of malignant transformation.

  • cancer genetics
  • cancer research
  • cancer
View Full Text

Statistics from


The immortalisation of cancer cells is a critical hallmark required for malignant behaviour.1 The reactivation of telomerase by tumours is the most common pathway contributing to the immortalised state, and in turn the most common somatic event to achieve this involves mutations in the promoter of telomerase reverse transcriptase (TERT), the catalytic subunit of telomerase. By contrast, deleterious germline TERT mutations have been shown to be associated with dyskeratosis congenita (a progeria) and pulmonary fibrosis. As a result, there is interest in understanding TERT, its regulation and dysregulation. More specifically, elucidating the molecular mechanism of how promoter mutations in TERT lead to increased expression of telomerase during carcinogenesis and how these alterations could potentially be exploited for diagnostic and therapeutic purposes is of great interest to researchers and clinicians.

The structure and function of TERT

The linear organisation of eukaryotic chromosomes results in two fundamental problems: first, the ends of the chromosomes being recognised as double-stranded breaks by the cell, and second the erosion of the 5’ end during cycles of genomic replication due to non-reproduction of the RNA primer binding site.2

The former problem is avoided by the presence of telomeres at the ends of chromosomes. Telomeres are tandem repeats of TTAGGG (in vertebrates and most metazoans3) which, when assembled with a protein complex known as shelterin, protect the ends of chromosomes from DNA repair pathways initiated by a DNA damage response.

The latter problem, known as the ‘end replication problem’, can be rectified by telomerase. The ribonucleoprotein telomerase has a core component composed of a reverse transcriptase (TERT) subunit and a separately coded RNA template (TERC or TR), which, along with a series of associate proteins, leads to the extension and replenishment of telomeres.

In humans, telomerase is normally expressed during development in embryonic stem cells and later silenced in somatic cells on differentiation.4 Telomerase expression is maintained to a restricted set of cells, primarily transit-amplifying stem-like cells and germ cells.

In the absence of telomere expansion, the proliferative capacity of human cells is limited by the continuous erosion of telomeres, leading to cellular senescence. The number of cellular divisions prior to senescence is known as the Hayflick limit.5 This senescence response is a critical tumour suppressive mechanism, and yet can be the source of various diseases as the result of short telomeres, such as lung fibrosis.6

The role of TERT in cancer

Telomerase is detectable in over 90% of human cancers,4 7 and its re-expression is thought to represent the most common pathway to cellular immortalisation. It has been shown that the increased expression of TERT leads to restoration of telomerase activity,8 9 thereby implicating the transcriptional control of TERT as a key factor in diseases, including ageing and cancer.

During neoplastic progression, cellular senescence is bypassed by the inactivation of cell cycle checkpoint genes such as p53 and pRb.10 With continuing cycles of cellular division past the point of replicative senescence (M1 stage), telomeres become critically shortened and cells enter ‘crisis’ (M2 stage). In crisis, chromosome end fusions and breakage-fusion-bridge events occur, leading to chromosomal instability. Cells escape crisis through either upregulation of telomerase or the alternate lengthening of telomeres mechanism.11 In the latter process, telomeres are replenished using homologous recombination.

TERT is located on chromosome 5 and consists of 16 exons.12 13 The protein product TERT exists as a dimer within the telomerase holoenzyme14 and consists of three regions: (1) the N-terminal extension that contains an N-terminal domain and a telomerase RNA-binding domain; (2) the central catalytic reverse transcriptase domain; and (3) the C-terminal extension.15 This basic organisation has remained remarkably stable over evolutionary time,16 implying that it was present in basal metazoans at the emergence of multicellularity. Interestingly, TERT is not present in Drosophila, as this genus does not use telomerase to solve the end replication problem.17

The promoter region of TERT has been extensively studied in order to identify the candidate factors involved in influencing TERT expression. (For a comprehensive review of the promoter structure and binding partners, see ref 18.) The TERT promoter is guanine-cytosine rich (GC-rich)and lacks both a TATA box and a CAAT box. Multiple factors have been shown to influence TERT expression in context-specific ways, either singly or in coordination, including Myc, oestrogen, SP1, nuclear factor kappa B (NF-κB), p53, activator protein 1 (AP-1) and E2F factors. Recognition sequences for binding of p53, p21, SP1, E26 transformation-specific (ETS), E2F, AP-1, hypoxia-inducible factor 1 (HIF1) and c-myc are present within the promoter region.18 Interestingly, the ETS family member gene GABPA, which binds TERT promoter mutations in cancer (described below), does not appear to bind the native promoter.19

Splice variants of TERT

While the transcriptional regulation of TERT has been studied in depth, recent work has evaluated the role of alternate splicing of mRNA transcripts. TERT can be translated from multiple differently spliced transcripts, with only the longest variant having reverse transcriptase enzymatic activity.20 Breast cancer cell lines with overexpression of transcripts without catalytic function have been shown to have reduced apoptosis, conferring a survival advantage.21 This suggests novel functions of TERT beyond telomere extension.

TERT upregulation in cancer/TERT promoter mutations

TERT can be upregulated in cancer through several mechanisms, including gene amplification, rearrangements and mutations within its promoter. TERT has been shown to be amplified in approximately 4% of cancers, especially ovarian cancer, lung adenocarcinoma, lung squamous cell carcinoma, oesophageal carcinoma and adrenocortical carcinoma.22 Rearrangements of the TERT promoter have been demonstrated in high-risk neuroblastomas.22 23 However, amplifications and rearrangements of TERT appear to be relatively rare overall in cancer, although common in specific subtypes.22

The identification of frequent non-coding TERT promoter mutations in cutaneous melanoma24 25 at once simultaneously delineated a novel class of cancer driver mutations, as well as indicated the mechanism by which TERT upregulation occurred in a large proportion of tumours. These mutations are recurrent C>T transitions occurring at chr5:1295228 (−124 or C228T) or chr5:1295250 (−146 or C250T) (hg19/GCRh37 genome coordinates) within the core promoter of TERT, leading to the creation of novel ETS transcription factor binding sites. Initial studies using a luciferase reporter assay demonstrated increased TERT gene expression as a result of these mutations.24

TERT promoter mutations were subsequently demonstrated across a range of malignancies. Of note, the frequency of TERT promoter mutations varies considerably with tumour subtype. In melanoma, up to 80% of non-acral cutaneous melanomas have been shown to have TERT promoter mutations,26–29 while less than 10% of acral melanomas30 and less than 1% of uveal melanomas31 have these mutations. In tumours of the central nervous system, TERT promoter mutations are present in approximately 70% of primary glioblastomas and oligodendrogliomas, but are relatively infrequent in secondary glioblastomas.32–35 TERT promoter mutations are also common in urothelial carcinoma,36 37 poorly differentiated and anaplastic thyroid carcinomas,38 39 cutaneous basal cell and squamous cell carcinomas,40 41 and hepatocellular carcinoma42 (comprehensively and recently reviewed in ref 43).

The mutations in C228T and C250T, which rarely co-occur,26 27 both lead to the creation of an identical 11-base sequence which corresponds to a de novo binding site for an ETS transcription factor (figure 1). Reporter assays have demonstrated that both C228T and C250T lead to increased transcription of TERT,24 25 approximately doubling wild-type promoter expression. Increased telomerase expression has also been demonstrated in urothelial carcinomas with TERT promoter mutations.36 Additionally, TERT promoter mutations are associated with switching of inactive to active chromatin marks in the TERT promoter.44 The likely ETS factor responsible for increased expression has been identified as GABPA,45 which is the only one of the 26 members of the ETS family that forms multimeric complexes when driving gene expression. A recent study examining glioblastoma cell lines found GABPβ1L to be the critical binding partner of GABPA in driving TERT expression in the presence of a TERT promoter mutation.19 Another group has suggested that the C228T and C250T mutations are functionally distinct: the former leading to GABPA recruitment; the latter leading to the generation of both an ETS site and a functional p52 site requiring ETS1/2 as the culpable ETS factor.46

Figure 1

TERT promoter mutations occur most commonly at two positions. Two C→T mutations located at −124 and −146 base pairs from the TSS within the core promoter of TERT account for the majority of TERT promoter mutations identified in cancer. These mutations lead to the creation of novel ETS transcription factor binding sites which drive increased expression of TERT. ETS, E26 transformation-specific; TERT, telomerase reverse transcriptase; TSS, transcriptional start site.

The mechanism by which TERT promoter mutations ultimately facilitate cancer growth is still being elucidated. Whereas the initial studies used reporter assays to demonstrate increased TERT expression, the demonstrated increase in TERT expression appears to be relatively modest, and several studies have failed to find a significant association between TERT promoter status and TERT expression.28 36 47 However, modest expression of TERT may still be sufficient for tumour cells to have a selective advantage.48 Comparison between matched naevi and adjacent melanoma demonstrates increased TERT expression in the malignant component with a TERT promoter mutation.49 A recent study by Chiba et al 50 demonstrated that, by contrast, telomere length was shorter in the melanomas than in the adjacent naevi.50 In this latter study, the investigators propose that TERT promoter mutations act in two stages, with the first phase having moderately increased TERT expression yet at a level insufficient to prevent telomere shortening, resulting in shorter telomeres and delayed replicative senescence. In the second phase, there is telomere-driven genomic instability and upregulated telomerase activity.

A recent systematic pan-cancer analysis of more than 2500 tumour genomes found very few potential recurrent non-coding driver point mutations aside from those in TERT.51 The pan-cancer analysis confirmed earlier results which did not find other non-coding mutations in cancer leading to changes in gene expression.47 Rather than being an exemplar of a potential novel class of non-coding driver mutations, TERT promoter mutations appear to be unique, likely a result of the peculiar biology of telomerase and its regulation.

Timing of TERT promoter mutations and their use as a biomarker

While TERT promoter mutations demonstrate that the cells of origin of specific tumours have had downregulated TERT at some point, it is not clear at what point during tumourigenesis these mutations are acquired. Given that the selective pressure for TERT promoter mutations should be strongest near the Hayflick limit after multiple rounds of replication,5 and therefore relatively late, it is somewhat unexpected that TERT promoter mutations are early events in carcinogenesis. Indeed, accumulating evidence suggests that TERT promoter mutations, at least in some tumours, are not an initiating event, but are selected for early in neoplasia, at an intermediate, preinvasive phenotype.52–54 As such, TERT promoter mutations are potentially a useful diagnostic biomarker, as these lesions can potentially be treated with curative intent. However, in certain lesions, TERT promoter mutation detection will not distinguish diagnostically between malignant and intermediate entities.

The promise of the use of TERT promoter mutations as a clinical biomarker for cancer are threefold: first, that these mutations appear as a manifestation of a specific hallmark of cancer (although not fully tested yet in benign tissue)1; second, that these occur early in tumour development49 52–55; and third, that these mutations are recurrent in relatively few genomic positions (with the two canonical −124 and −146 point mutations accounting for over 85% of described mutations) in a range of malignancies.43 55

TERT promoter mutations have multiple potential uses as clinical biomarkers. TERT promoter mutations can be detected in urine samples from patients with recurrent urothelial carcinoma.56 In melanoma, several approaches using droplet digital PCR have been recently developed57 58 which can monitor TERT promoter mutations in serum. Moreover, TERT promoter mutation detection indicates a worse prognosis in thyroid malignancies,59 melanoma27 and gliomas.60 61

TERT in conditions other than cancer

Germline mutations in TERT have been associated with idiopathic pulmonary fibrosis,62 and rare cases of germline mutations in TERT have been shown in families with dyskeratosis congenita.63 TERT mutations have also been found in patients with severe emphysema.64 Interestingly, somatic mutations in the TERT promoter have been found in the leucocytes of some individuals with germline mutations in TERT, suggesting that these mutations act as counterbalances to one another regarding TERT expression.65


The TERT gene plays important roles in normal biology, and perturbations of its regulation play a critical role in a variety of pathological states, especially neoplasia. In particular, TERT plays a central role in modulating telomerase activity in tumours, conferring the hallmark of immortality on neoplastic clones. A deeper understanding of this gene is pertinent given its potential usage as a biomarker and the future development of possible therapeutic avenues.


View Abstract


  • Handling editor Des Richardson.

  • Contributors AJC was the main author. All authors contributed to the conception of the work and revising it critically, and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.